Bear wrote - "-Don showed 5 cohorts (presumably different doses). Cohorts 2, 3 and 4 are all looking really good with several patients ongoing (without progression) at week 18 to 64. The 3 rock stars in cohort 2 currently at around week 64 stand out. Cohort 5 is ongoing but too early to tell yet if effective. Cohort 1 had one patient that made it to 46 weeks (the rest progressed at 10-22 weeks)."

I spent lot's of time looking at the graph on p17 yesterday and it gave me a very good feeling but the central issue to me is what defines the cohorts. If it is dosages that is one thing but did Don state that? If it is screening conditions like the state of the patients disease that is another important. I'm going to email Zenith tomorrow for clarity. Why would Don not make this completely clear (apologies if he did).

Any insight here would be great. I haven't listened to the presentation yet but the comments suggest it's positive.

Toinv